This company is no longer active
TLGT.Q Stock Overview
Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Teligent, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0002 |
| 52 Week High | US$0.63 |
| 52 Week Low | US$0.0001 |
| Beta | 1.21 |
| 1 Month Change | 0% |
| 3 Month Change | -80.00% |
| 1 Year Change | -99.96% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| TLGT.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -6.4% | 0.3% |
| 1Y | -100.0% | -10.0% | 8.0% |
Return vs Industry: TLGT.Q underperformed the US Pharmaceuticals industry which returned -4.4% over the past year.
Return vs Market: TLGT.Q underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| TLGT.Q volatility | |
|---|---|
| TLGT.Q Average Weekly Movement | 884.8% |
| Pharmaceuticals Industry Average Movement | 10.9% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: TLGT.Q's share price has been volatile over the past 3 months.
Volatility Over Time: TLGT.Q's weekly volatility has increased from 438% to 885% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1977 | 146 | n/a | www.teligent.com |
Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets.
Teligent, Inc. Fundamentals Summary
| TLGT.Q fundamental statistics | |
|---|---|
| Market cap | US$18.56k |
| Earnings (TTM) | -US$91.57m |
| Revenue (TTM) | US$46.30m |
0.0x
P/S Ratio0.0x
P/E RatioIs TLGT.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLGT.Q income statement (TTM) | |
|---|---|
| Revenue | US$46.30m |
| Cost of Revenue | US$55.28m |
| Gross Profit | -US$8.98m |
| Other Expenses | US$82.58m |
| Earnings | -US$91.57m |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | -19.41% |
| Net Profit Margin | -197.78% |
| Debt/Equity Ratio | -267.7% |
How did TLGT.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/27 18:08 |
| End of Day Share Price | 2022/07/27 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Teligent, Inc. is covered by 8 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dewey Steadman | Canaccord Genuity |
| Donald Ellis | Citizens JMP Securities, LLC |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |